Please click on the link you are interested in to view interviews with some of the speakers at Drug Discovery 2018.
Nav1.7 selective blockers and their current status of development
Dr Zahid Ali, Mundipharma Research and Development, explains selective Nav1.7 blockers and why they are important for analgesic research. He also outlines their current status of development.
A business model for open drug discovery
Dr Aled Edwards, Structural Genomics Consortium, discusses the aims and benefits of open drug discovery approach
Advanced human cellular assays
Professor Steve Anderton, Concept Life Sciences discusses advanced human cellular assays
Applying deep learning architectures to de novo molecular drug design
Dr Ola Engkvist, AstraZeneca, outlines how deep learning architectures are being applied to drug discovery
Assessing and addressing biopharmaceutical aggregation
Dr David Brockwell, University of Leeds, explains aggregation and why protein-based pharmaceuticals are particularly susceptible to it.
Chemical linkers in antibody drug conjugate development
Dr Mark Frigerio, Abzena, explains the importance of chemical linkers for ADCs and the challenges associated with their development.